Cargando…
A validated UHPLC-MS/MS method for rapid determination of senicapoc in plasma samples
The clinically tested KCa3.1 channel blocker, senicapoc, has been proven to have excellent pharmacological properties and prior clinical trials found it to be safe for use in patients with sickle cell anaemia. Currently, several preclinical projects are aiming to repurpose senicapoc for other indica...
Autores principales: | Sørensen, Lambert K., Petersen, Asbjørn, Granfeldt, Asger, Simonsen, Ulf, Hasselstrøm, Jørgen B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869607/ https://www.ncbi.nlm.nih.gov/pubmed/33626443 http://dx.doi.org/10.1016/j.jpba.2021.113956 |
Ejemplares similares
-
Treatment with senicapoc in a porcine model of acute respiratory distress syndrome
por: Petersen, Asbjørn G., et al.
Publicado: (2021) -
Senicapoc treatment in COVID‐19 patients with severe respiratory insufficiency—A randomized, open‐label, phase II trial
por: Granfeldt, Asger, et al.
Publicado: (2022) -
Effect of the KCa3.1 blocker, senicapoc, on cerebral edema and cardiovascular function after cardiac arrest — A randomized experimental rat study
por: Hansen, Frederik Boe, et al.
Publicado: (2021) -
Development and Validation of a UHPLC–MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples
por: Charlier, Bruno, et al.
Publicado: (2022) -
Sensitive and Rapid UHPLC-MS/MS for the Analysis of Tomato Phenolics in Human Biological Samples
por: Martínez-Huélamo, Miriam, et al.
Publicado: (2015)